middle.news
Radiopharm Reports 93% Concordance for RAD101, Plans Phase 3 Trial
8:22am on Wednesday 22nd of July, 2026 AEST
•
Healthcare
Read Story
Radiopharm Reports 93% Concordance for RAD101, Plans Phase 3 Trial
8:22am on Wednesday 22nd of July, 2026 AEST
Key Points
RAD101 Phase 2b trial achieved 93% PET-MRI concordance
Preliminary 86% sensitivity in detecting recurrent brain metastases
RAD101 granted FDA Fast Track and partnered with Siemens Healthineers
RAD204 Phase 1 trial shows durable partial responses and favorable safety
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE